Skip to content

The Good, the Bad and the Ugly (Part 1)

18nov12:00 pm2:00 pmThe Good, the Bad and the Ugly (Part 1)What lessons have come out of the last years?12:00 pm - 2:00 pm

Event Details

This is the first of two parts to this webinar series.

At the start of 2020, most faced changes to the way we work with the spread of COVID-19. Employers and employees embraced a new virtual workspace. Changes were quickly introduced leaving little time for contemplation, planning or preparation.

In this first part, our speakers will present on Challenges of home working and future working practice:

  • Tim Hardman will use findings of two broad surveys of the Pharma industry. An early survey of pharma people found that everyone faced personal disruption and change, many people quickly showed signs of isolation and depression.

    At 12 months, nations such as the UK were considering the potential to reverse lockdown conditions. Enlightened employers and employees were asking themselves whether lessons learned during the pandemic may be translated into new working paradigms. A second survey was conducted to gain insight into thoughts regarding future working at the time of rising pressure to return to offices and the old way of working.

  • Simon Chell will talk about a change process to transform the work/life balance of a group that were feeling stress from over a year of working from home.

We will run a short workshop session, and of course you will be able to ask questions and network with like-minded colleagues.

NOTE – Part 2 will run on 29th November and will feature Daniel de Dosza, speaking on future pandemics (or similar challenges!) and contingency planning.

Note that the small cost to attend this part will also cover the second part.

Speakers for this event

  • Simon Chell

    Simon Chell

    leader, Discovery Biology UK & US, AstraZeneca

    Simon obtained his PhD at Bristol University studying the function of prostaglandins in colorectal cancer. Subsequent research into fundamental cancer biology at the Babraham Institute (Cambridge, UK) and the Friedrich Miescher Institute (Basel, Switzerland) led to Simon joining GSK in 2007 where he progressed to Senior Director in roles of increasing scientific responsibility – latterly, as Senior Scientific Director for GSK’s clinical research activities in sub-Saharan Africa. Simon joined AstraZeneca in 2018 and currently leads UK & US Discovery Biology in Discovery Sciences, Biopharmaceutical R&D, where he is responsible for the delivery of therapeutic programs, technological innovations and new drug formats through a multidisciplinary department incorporating cell, molecular, biochemical and protein sciences. Simon is a Fellow of the Royal Society of Biology, an Investment Committee member of Apollo Therapeutics and a core member of ELRIG’s Science Strategy Committee. He has extensive experience in medicine creation and has led international functions and major public-private alliances across the fields of drug discovery, new drug formats and early clinical research.

    leader, Discovery Biology UK & US, AstraZeneca

  • Tim Hardman

    Tim Hardman

    Managing Director, Niche

    Managing Director, Niche

Virtual Event Details

Event has already taken place!


November 18, 2021 12:00 pm - 2:00 pm

Book now

Tickets are not available for sale any more for this event!

Back To Top